We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
-11.53%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$842M
AUM Growth
-$295M
(-26%)
Cap. Flow
-$112M
Cap. Flow
% of AUM
-13.31%
Top 10 Holdings %
Top 10 Hldgs %
47.05%
Holding
143
New
42
Increased
27
Reduced
21
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtriCure
ATRC
|
+$14M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$11.9M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$9.5M |
| 4 |
SI-BONE Inc
SIBN
|
+$9.49M |
| 5 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
+$7.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GRFS
Grifois
GRFS
|
+$13.5M |
| 2 |
AGN
Allergan plc
AGN
|
+$13.3M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$7.52M |
| 4 |
CONMED
CNMD
|
+$5.18M |
| 5 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$4.53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.76% |
| 2 | Industrials | 1.16% |
| 3 | Consumer Staples | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
DexCom
DXCM
$34.3B
| $10M | 1.19% |
148,732
-71,596
| -32% | -$4.46M |
|
|
RCM
27
DELISTED
R1 RCM Inc. Common Stock
RCM
| $9.76M | 1.16% |
1,073,943
+264,333
| +33% | +$3.18M |
|
|
XENT
28
DELISTED
Intersect ENT, Inc
XENT
| $8.08M | 0.96% |
681,865
-48,495
| -7% | -$1.08M |
|
|
INOV
29
CALL
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $7.91M | 0.94% |
475,000
+366,000
| +336% | +$6.95M |
|
30
PUT
Thermo Fisher Scientific
TMO
$223B
| $7.8M | 0.93% |
+27,500
| New | +$8.67M |
|
|
XLRN
31
DELISTED
Acceleron Pharma
XLRN
| $6.89M | 0.82% |
+76,681
| New | +$5.96M |
|
|
MNTA
32
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $6.7M | 0.8% |
246,214
+82,724
| +51% | +$2.3M |
|
|
QTNT
33
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $6.64M | 0.79% |
42,016
+14,756
| +54% | +$3.86M |
|
34
PUT
iShares MSCI USA Momentum Factor ETF
MTUM
$26B
| $6.39M | 0.76% |
+60,000
| New | +$7.42M |
|
|
35
SI-BONE Inc
SIBN
$851M
| $6.17M | 0.73% |
+516,476
| New | +$9.49M |
|
36
OrthoPediatrics
KIDS
$649M
| $5.89M | 0.7% |
148,513
-94,879
| -39% | -$4.25M |
|
|
CPRX
37
DELISTED
Catalyst Pharmaceutical
CPRX
| $5.57M | 0.66% |
+1,446,953
| New | +$5.94M |
|
38
Regeneron Pharmaceuticals
REGN
$82.1B
| $5.47M | 0.65% |
+11,212
| New | +$4.62M |
|
39
Adaptive Biotechnologies
ADPT
$4.01B
| $5.42M | 0.64% |
195,000
+140,990
| +261% | +$3.93M |
|
|
VAR
40
PUT
DELISTED
Varian Medical Systems, Inc.
VAR
| $5.39M | 0.64% |
+52,500
| New | +$6.93M |
|
|
PROF
41
Profound Medical
PROF
$253M
| $5.28M | 0.63% |
+542,256
| New | +$7.03M |
|
42
Twist Bioscience
TWST
$7.86B
| $5.28M | 0.63% |
+172,670
| New | +$4.64M |
|
43
QuidelOrtho
QDEL
$1.02B
| $5.09M | 0.6% |
+51,999
| New | +$4.21M |
|
44
CALL
Sarepta Therapeutics
SRPT
$1.94B
| $4.89M | 0.58% |
+50,000
| New | +$5.72M |
|
45
CALL
Gilead Sciences
GILD
$168B
| $4.11M | 0.49% |
+55,000
| New | +$3.8M |
|
46
Boston Scientific
BSX
$74.5B
| $4.08M | 0.48% |
+125,000
| New | +$4.88M |
|
|
AVDL
47
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.94M | 0.47% |
496,660
+387,660
| +356% | +$2.98M |
|
48
PUT
KALA BIO
KALA
$17M
| $3.84M | 0.46% |
+175
| New | +$2.8M |
|
49
Guardant Health
GH
$22.2B
| $3.79M | 0.45% |
54,475
-5,485
| -9% | -$421K |
|
|
50
Gilead Sciences
GILD
$168B
| $3.74M | 0.44% |
+50,000
| New | +$3.45M |
|
Similar funds
BCA
RC
DOFI
SCI
LPC
GBCP
SCTC
M
Pura Vida Investments's Q1 2020 Portfolio in Review
As of Q1 2020, Pura Vida Investments held 143 positions worth $842M, down 26% from $1.14B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Pura Vida Investments withdrew a net $112M in Q1 2020, closing 50 positions and reducing 21 holdings. Its most notable exit was Grifois, an estimated $13.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 26% a quarter earlier, followed by Industrials and Consumer Staples.
Against the trend, Pura Vida Investments opened a new position in AtriCure worth $13.1M.
- Pura Vida Investments's largest Q1 2020 buy was AtriCure: 388,994 shares worth $13.1M.
- Pura Vida Investments added most to Alexion Pharmaceuticals in Q1 2020, an estimated $11.9M increase.
- Pura Vida Investments's biggest Q1 2020 reduction was DexCom, cutting an estimated $4.46M.
- Pura Vida Investments fully exited Grifois in Q1 2020, selling an estimated $13.5M.
- Pura Vida Investments's ten largest holdings make up 47% of its $842M portfolio in Q1 2020.
- Pura Vida Investments opened 42 new positions and closed 50 in Q1 2020.
- Pura Vida Investments's portfolio value fell 26% quarter-over-quarter to $842M.
Based on Pura Vida Investments's 13F filing for Q1 2020, filed 15 May 2020.